Prokinetics and fundic relaxants in upper functional GI disorders

被引：106

作者：

Tack, Jan ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Ctr Gastroenterol Res, Louvain, Belgium

来源：

CURRENT OPINION IN PHARMACOLOGY | 2008年 / 8卷 / 06期

关键词：

D O I：

10.1016/j.coph.2008.09.009

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Gastrointestinal prokinetics are a heterogeneous class of drugs that stimulate smooth muscle contractions to enhance gastric emptying and intestinal transit. Recently studied prokinetics include antidopaminergic agents (itopride), serotonergic agents (tegaserod and others), and motilin receptor agonists and ghrelin receptor agonists (mitemcinal, TZP101). It has been difficult to establish symptomatic benefit with prokinetic drugs in gastroparesis and functional dyspepsia, because of pathophysiological heterogeneity of the patient populations, a lack of well-accepted endpoints, and inconsistent relationships between changes in motor function and symptomatic outcome. Fundic relaxant drugs are a recent different approach to treatment of gastric motility disorders. Recently studied drugs include drugs under investigation including nitrates, serotonin reuptake blockers, 5-HT1A receptor agonists (buspirone and R137696), and muscarinc M1/M2 receptor antagonists (acotiamide or Z-338).

引用

页码：690 / 696

页数：7

共 73 条

[1] Treatment of gastroparesis: a multidisciplinary clinical review [J].

Abell, TL ;

Bernstein, RK ;

Cutts, T ;

Farrugia, G ;

Forster, J ;

Hasler, WL ;

McCallum, RW ;

Olden, KW ;

Parkman, HP ;

Parrish, CR ;

Pasricha, PJ ;

Prather, CM ;

Soffer, EE ;

Twillman, R ;

Vinik, AI .

NEUROGASTROENTEROLOGY AND MOTILITY, 2006, 18 (04) :263-283

[2]

ANG D, 2008, NEUROGASTRO IN PRESS

[3] Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis [J].

Arts, J. ;

Holvoet, L. ;

Caenepeel, P. ;

Bisschops, R. ;

Sifrim, D. ;

Verbeke, K. ;

Janssens, J. ;

Tack, J. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (09) :1251-1258

[4] Influence of intrapyloric botulinum toxin injection on gastric emptying and meal-related symptoms in gastroparesis patients [J].

Arts, J. . ;

Van Gool, S. ;

Caenepeel, P. ;

Verbeke, K. ;

Janssens, J. ;

Tack, J. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (04) :661-667

[5] The in vivo gastrointestinal activity of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity [J].

Beattie, D. T. ;

Armstrong, S. R. ;

Shaw, J. -P. ;

Marquess, D. ;

Sandlund, C. ;

Smith, J. A. M. ;

Taylor, J. A. ;

Humphrey, P. P. A. .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2008, 378 (01) :139-147

[6] The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo [J].

Beattie, DT ;

Smith, JAM ;

Marquess, D ;

Vickery, RG ;

Armstrong, SR ;

Pulido-Rios, T ;

McCullough, JL ;

Sandlund, C ;

Richardson, C ;

Mai, N ;

Humphrey, PPA .

BRITISH JOURNAL OF PHARMACOLOGY, 2004, 143 (05) :549-560

[7] The influence of the novel 5-HT1A agonist R137696 on the proximal stomach function in healthy volunteers [J].

Boeckxstaens, G. E. ;

Tytgat, G. N. ;

Wajs, E. ;

Van Nueten, L. ;

De Ridder, F. ;

Meulemans, A. ;

Tack, J. .

NEUROGASTROENTEROLOGY AND MOTILITY, 2006, 18 (10) :919-926

[8] Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder [J].

Bouras, EP ;

Camilleri, M ;

Burton, DD ;

Thomforde, G ;

McKinzie, S ;

Zinsmeister, AR .

GASTROENTEROLOGY, 2001, 120 (02) :354-360

[9] Pharmacodynamic effects of a novel prokinetic 5-HT4 receptor agonist, ATI-7505, in humans [J].

Camilleri, M. ;

Vazquez-Roque, M. I. ;

Burton, D. ;

Ford, T. ;

Mckinzie, S. ;

Zinsmeister, A. R. .

NEUROGASTROENTEROLOGY AND MOTILITY, 2007, 19 (01) :30-38

[10] A placebo-controlled trial of prucalopride for severe chronic constipation [J].

Camilleri, Michael ;

Kerstens, Rene ;

Rykx, An ;

Vandeplassche, Lieve .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (22) :2344-2354

← 1 2 3 4 5 6 7 8 →